Anti-Tigit Antibodies (2018)
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application PCT/US2018/043968, filed Jul 26, 2018. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,329,349 | Anti-Tigit Antibodies In force · High confidence UsedRemaining | Iteos Belgium S.A. | In force | High confidence | ||
| US 11,439,705 | Anti-Tigit Antibodies In force · High confidence | Iteos Belgium S.A. | In force | High confidence | ||
| Application 16/634,506 | Anti-Tigit Antibodies Abandoned Abandoned Dec 5, 2021 | Iteos Belgium S.A. | Abandoned | Abandoned Dec 5, 2021 | ||
| Application 17/872,494 | Anti-TIGIT Antibodies Abandoned Abandoned Dec 31, 2025 | Iteos Belgium S.A. | Abandoned | Abandoned Dec 31, 2025 | ||
| Application 17/946,158 | Anti-TIGIT Antibodies Abandoned Abandoned Oct 28, 2024 | Iteos Belgium S.A. | Abandoned | Abandoned Oct 28, 2024 |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Iteos Belgium S.A..
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.